ScholarIQanswers from OpenAlex

Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review

PaperCitations, authors & open-access status

Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review have?

ScholarIQcitation count

Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review has 9 citations in the OpenAlex counts ScholarIQ stores.

When was Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review published?

ScholarIQyear

Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review has 2015 year in the ScholarIQ index.

What is the open-access status of Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review?

ScholarIQoa status

Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review has green oa status in the ScholarIQ index.

What is the DOI of Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review?

ScholarIQdoi

The DOI for Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review is on the source record.

What is the PMID of Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review?

ScholarIQpmid

The PMID for Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review is on the source record.

What is the OpenAlex record for Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review?

ScholarIQopenalex

The OpenAlex for Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial